Gemelli Biotech is a specialty biotechnology company that strives to achieve a thriving global family of healthy individuals by unlocking the potential of the microbiome. Gemelli’s mission is to support the discovery of novel diagnostics and therapeutics for the human microbiome by bringing biotechnology innovations to market in a fiscally responsible and socially conscious way.
Gemelli Biotech is proud to partner closely with Cedars-Sinai Medical Center in Los Angeles, ranked by US News and World Report as one of the top 10 hospitals in the nation. The Medically Associated Science and Technology (MAST) program at Cedars-Sinai is dedicated to the development of lab tests, drugs and devices to diagnose and treat patients and works closely with Gemelli. Alignment with MAST allows Gemelli to operate on the cutting edge, with an early look at the newest scientific discoveries related to the microbiome.
In the fall of 2018, Gemelli launched ibs-smart, the groundbreaking blood test for Mixed-Type and Diarrhea Predominant Irritable Bowel Syndrome. An exciting pipeline of innovation is set to follow in 2019.
Location: United States, North Carolina, Raleigh
Funding Rounds 2
Mentions in press and media 4